Asciminib was active in heavily pretreated patients with CML who had resistance to or unacceptable side effects from TKIs, including patients in whom ponatinib had failed and those with a T315I mutation. nej.md/2E6Ptxk

Editorial: Introduction to a How I Treat series on major complications after allogeneic stem cell transplantation ow.ly/bgQ050zA5oX

So proud of Jennifer Miller and her research presentation at ASH! :)

Wonderful presentation on the Updates from ASH 2020 from Cindy Herrera, PharmD, BCOP at TCT this year! If you didn’t catch it, make sure to go back and watch! I was lucky enough to collaborate with her and present the second half! #TCTM21 #oncopharm Lurie Cancer Center Northwestern Medicine

Had a great time seeing past & current Northwestern Medicine colleagues Barbara Pro @reemkarmali Daniel Wojenski at Ultmann Chicago Lymphoma Conference Lurie Cancer Center

Northwestern Pride! 💜🏳️‍🌈 Daniel Wojenski Brendan @jerbunnyman